What LEVI-04 data suggest about the future of disease-modifying osteoarthritis therapies
LEVI-04 Phase II data from Levicept Ltd. signal a shift in osteoarthritis treatment. Discover what this means for disease-modifying therapies.
Pharma & Biotech
Pharma & Biotech
4Moving Biotech wins FDA Fast Track for 4P004, but can it finally change the knee osteoarthritis treatment playbook?
4Moving Biotech’s 4P004 won FDA Fast Track in knee osteoarthritis. Read what this means for DMOAD development, trial risk, and regulatory strategy.